Mini-Tumors in a dish could predict best cancer therapy
NCT ID NCT06612827
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether tiny lab-grown copies of a patient's tumor, called organoids, can help predict which cancer treatment will work best. Researchers will collect tumor and blood samples from 20 people with undifferentiated carcinoma before they start standard therapy. They will grow organoids from these samples and test different drugs on them, then compare the lab results with how the patient actually responds to treatment. The goal is to see if this method can guide personalized treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tumor organoid testing
- What this could lead to
- If successful, this approach could help doctors choose the most effective treatment for each patient with undifferentiated carcinoma, improving outcomes.
- What could go wrong
- This is a very small, early-stage study (20 participants) focused on feasibility. The organoid predictions may not match real patient responses, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNDIFFERENTIATED CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre François Baclesse
RECRUITINGCaen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.